Identification of leukemia-associated immunophenotypes by database-guided flow cytometry provides a highly sensitive and reproducible strategy for the study of measurable residual disease in acute myeloblastic leukemia
Authors:
Preprint
Abstract
Background Multiparametric Flow Cytometry (MFC) is an essential tool to study the involved cell lineages, the aberrant differentiation/maturation patterns and the expression of aberrant antigens in acute myeloid leukemia (AML). The characterization of leukemia-associated immunophenotypes (LAIPs) at the moment of diagnosis is critical to establish reproducible strategies for the study of measurable residual disease using MFC (MFC-MRD). Methods In this study, we identified and characterized LAIPs by comparing the leukemic populations of 145 AML patients, using the EuroFlow AML/ MDS MFC panel, with 6 databases of normal myeloid progenitors (MPCs). Principal component analysis was used to identify and characterize the LAIPs, which were then used to generate individual profiles for MFC-MRD monitoring. Furthermore, we investigated the relationship between the expression patterns of LAIPs and the different subtypes of AML. The MFC-MRD study was performed by identifying residual AML populations that matched with the LAIPs at diagnosis. To further validate this approach, the presence of MRD was also assessed by qPCR (qPCR-MRD). Finally, we studied the association between MFC-MRD and progression-free survival (PFS). Results The strategy used in this study allowed us to describe more than 300 different LAIPs and facilitated the association of specific phenotypes with certain subtypes of AML. The MFC-MRD monitoring based on LAIPs with good/strong specificity was applicable to virtually all patients and showed a good correlation with qPCR-MRD and PFS. Conclusions The described methodology provides an objective method to identify and characterize LAIPs. Furthermore, it provides a theoretical basis to develop highly sensitive MFC-MRD strategies.Keywords
This publication has 31 references indexed in Scilit:
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Leukemia‐associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findingsInternational Journal of Laboratory Hematology, 2014
- Tumor heterogeneity makes AML a “moving target” for detection of residual diseaseCytometry Part B: Clinical Cytometry, 2013
- CD117‐CD15 in acute myeloid leukemia: no role as LAIP in the study of minimal residual diseaseEuropean Journal of Haematology, 2013
- EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocolsLeukemia, 2012
- EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytesLeukemia, 2012
- Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasmsBritish Journal of Haematology, 2011
- Incidence, Sensitivity, and Specificity of Leukemia-Associated Phenotypes in Acute Myeloid Leukemia Using Specific Five-Color Multiparameter Flow CytometryAmerican Journal of Clinical Pathology, 2008
- The leukemic stem cellBest Practice & Research Clinical Haematology, 2007
- Molecular detection of t(8;21)/AML1‐ETO in AML M1/M2: correlation with cytogenetics, morphology and immunophenotypeBritish Journal of Haematology, 1996